These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30132336)

  • 41. Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.
    Price MJ
    Interv Cardiol Clin; 2017 Jan; 6(1):39-47. PubMed ID: 27886821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Yerasi C; Case BC; Chezar-Azerrad C; Forrestal BJ; Medranda GA; Shea C; Zhang C; Ben-Dor I; Satler LF; Bernardo NL; Hashim H; Garcia-Garcia HM; Waksman R
    Am Heart J; 2021 Aug; 238():59-65. PubMed ID: 33961829
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.
    Marcano AL; Ferreiro JL
    Curr Atheroscler Rep; 2016 Nov; 18(11):66. PubMed ID: 27714642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cangrelor in patients undergoing cardiac surgery: the BRIDGE study.
    Voeltz MD; Manoukian SV
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):811-6. PubMed ID: 23895024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cangrelor - Expanding therapeutic options in patients with acute coronary syndrome.
    Kubica J; Adamski P; Dobrzycki S; Gajda R; Gąsior M; Gierlotka M; Jaguszewski M; Legutko J; Lesiak M; Navarese EP; Niezgoda P; Ostrowska M; Pawłowski T; Tycińska A; Umińska JM; Witkowski A; Gil R
    Cardiol J; 2024; 31(1):133-146. PubMed ID: 37964649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
    Abnousi F; Sundaram V; Yong CM; Prats J; Deliargyris EN; Stone GW; Hamm CW; Steg PG; Gibson CM; White HD; Price MJ; Généreux P; Desai M; Yang L; Ding VY; Harrington RA; Bhatt DL; Mahaffey KW
    Am Heart J; 2017 Jun; 188():147-155. PubMed ID: 28577670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
    Droppa M; Vaduganathan M; Venkateswaran RV; Singh A; Szumita PM; Roberts RJ; Qamar A; Hack L; Rath D; Gawaz M; Fuernau G; de Waha-Thiele S; Desch S; Schneider S; Ouarrak T; Jaffer FA; Zeymer U; Thiele H; Bhatt DL; Geisler T
    Resuscitation; 2019 Apr; 137():205-212. PubMed ID: 30790690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
    White HD; Chew DP; Dauerman HL; Mahaffey KW; Gibson CM; Stone GW; Gruberg L; Harrington RA; Bhatt DL
    Am Heart J; 2012 Feb; 163(2):182-90.e4. PubMed ID: 22305835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
    Tamborini Permunian E; Riva N; Guasti L; Squizzato A
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current status of data on cangrelor.
    Qamar A; Bhatt DL
    Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.
    Peterson BE; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
    Circ Cardiovasc Interv; 2022 Mar; 15(3):e011069. PubMed ID: 35196863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of Cangrelor as a Bridge to Left Ventricular Assist Device Implantation in a Patient with a Recent Drug-Eluting Stent Who Developed Acute Tirofiban-Related Thrombocytopenia.
    Kabadi RA; Danelich IM; Entwistle JW; Marhefka GD; Reeves G; Boyle AJ; Qureshi AM
    Pharmacotherapy; 2019 Apr; 39(4):521-525. PubMed ID: 30644585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perioperative Antiplatelet Bridging With Cangrelor: A Cohort Study and Narrative Review.
    Salgia A; Krueger CK; Gillette MA
    Ann Pharmacother; 2023 May; 57(5):544-552. PubMed ID: 36004393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel Use of Cangrelor With Heparin During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Who Require Cardiovascular Surgery: A Case Series.
    Gernhofer YK; Banks DA; Golts E; Pretorius V
    Semin Thorac Cardiovasc Surg; 2020 Winter; 32(4):763-769. PubMed ID: 31610233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study.
    Johnson BV; Horton ER; Domenico C; Nathan AS; Fanaroff AC; Acker MA; Kolansky DM
    J Invasive Cardiol; 2021 Dec; 33(12):E998-E1003. PubMed ID: 34817395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.